A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder - Stanford University (ClinicalTrials.gov, 2026)

An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal Cancers - University of Nebraska (ClinicalTrials.gov, 2026)

Magic mushroom compound shows promise against cocaine addiction. - Nuwer R (Science (New York, N.Y.), 2026)

Human brain changes after first psilocybin use - Lyons T.; Spriggs M.; Kerkelä L.; Rosas F. E.; Roseman L.; Mediano P. A. M.; Timmermann C.; Oestreich L.; Pagni B. A.; Zeifman R. J.; Hampshire A.; Trender W.; et al. (Nature Communications, 2026)

A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control - Usona Institute (ClinicalTrials.gov, 2026)

A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression - University of Washington (ClinicalTrials.gov, 2026)

Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder - University of California; Los Angeles (ClinicalTrials.gov, 2026)

Effects of Psilocybin Treatment on Cognitive Effort Avoidance in Major Depressive Disorder and Co-Occurring Alcohol Use Disorder - Sayali Ceyda; Weisman Eli; Barrett Frederick (JoCN Forum, 2026)

Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial - Lakshmi N Yatham (ClinicalTrials.gov, 2026)

Sa1731 A PILOT STUDY OF OPEN-LABEL PSILOCYBIN-ASSISTED THERAPY IN TREATMENT-REFRACTORY IBS - Mauney Erin; Zambrano Juliana; Clukey Jenna; Burton-Murray Helen; Datko Michael; Napadow Vitaly; Kuo Braden; King Franklin (Gastrointestinal Endoscopy, 2026)

Sex-Specific Effects of Psilocin on Paraventricular Nucleus of the Thalamus (PVT) Circuitry and Threat Responding Behavior in Male and Female Rats - Herman Melissa (Biological Psychiatry, 2026)

Prohedonic Effects of Psilocybin (COMP360) in a Touchscreen-Based Rodent Probabilistic Reward Task (Abstract ID: 227883) - LaMalfa Kayleigh; Pizzagalli Diego A.; Bergman Jack; Thomas Christopher W.; Kangas Brian (The Journal of Pharmacology and Experimental Therapeutics, 2026)

Acute Effects of 4-Bromo-2,5-Dimethoxyphenethylamine (2C-B) Compared With Psilocybin and MDMA in Healthy Participants - Holze Friederike; Arikci Denis; Thomann Jan; Rudin Deborah; Luethi Dino; Liechti Matthias E. (Biological Psychiatry, 2026)

PDE4B Inhibition and Psilocybin as Promising Approaches for Treating Methamphetamine Use Disorder: Preclinical Evidence From Rat Models (Abstract ID: 232554) - Hayduk Sean; Stringer Amy; Zagorski Satoria; Ward Sara Jane (The Journal of Pharmacology and Experimental Therapeutics, 2026)

Profiling the Cell-Type Specific Effects of Psilocybin in Medial Prefrontal Cortexh - Schuler Heike; Zhou Delong; Savignac Chloé; Cvetkovska Vedrana; Tse Yiu-Chung; Meccia Juliet; Bzdok Danilo; Bagot Rosemary (Biological Psychiatry, 2026)

356. Psilocybin Therapy is Associated With Decreases in Markers of Mitochondrial Stress and Inflammation in an Open-Label Clinical Trial of Parkinson’s Disease - Bradley Ellen; Kelley D Parker; Picard Martin; Szigeti Balazs; Sakai Kimberly; Fernandes Gisele; Ostrem Jill; Tanner Caroline; Finley Patrick; Ludwig Connie; Llerena Katiah; Busby Zach; et al. (Biological Psychiatry, 2026)

483. Acute Functional Brain Changes Associated With Psilocybin in Depression and Healthy Adults: A Systematic Review and Coordinate-Based Meta-Analysis - Poulin Joshua; Viulet Nic; Liu Ashley; MacIntosh Bradley J.; Nestor Sean M. (Biological Psychiatry, 2026)

Pure psilocybin reduces reward-associated preference while mushroom extract shows transient exploratory effects in rats - Andreia Machado Brito-da-Costa; Francisco Sacadura; Ricardo Jorge Dinis-Oliveira; Áurea Madureira-Carvalho; Diana Dias da Silva (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2026)

C29-12 Psilocybin Treatment Could Improve Outcomes for Age-associated Lung Diseases - Hecker L; Kleinhenz J M; Coarfa C; Kato K (American Journal of Respiratory and Critical Care Medicine, 2026)

Prevalence and Correlates of Past-Year Psilocybin Use in the U.S., 2024, USA - Yockey R. Andrew; Amis Amber; Devier Elise; Apu Aminul; Hoopsick Rachel (AJPM Focus, 2026)

Effects of Psilocybin on Attentional Set-Shifting Following Chronic Unpredictable Stress in Rats (Abstract ID: 231339) - Hennessey Joseph; Mantsch John; McCorvy John (The Journal of Pharmacology and Experimental Therapeutics, 2026)

Preclinical evaluation of psilocybin and related compounds: Inhibition of cytochrome P450 isoforms - Mariana Silva-Carvalho; Andreia Machado Brito-da-Costa; Ricardo Dinis-Oliveira; Áurea Madureira-Carvalho; Diana Dias-da-Silva (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2026)

SAT-219 Hepatic 5-HT2B receptor antagonism mediates the anti-steatotic and antifibrotic effects of psilocybin in preclinical MASH models - Signor Anna; Colognesi Martina; Finzi Giovanna; Gabbia Daniela; Mattarei Andrea; Comai Stefano; Pasut Gianfranco; Folli Franco; Manfredi Paolo; De Martin Sara (Journal of Hepatology, 2026)

6. Open-Label Extension of Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Continued Safety and Short-Term Efficacy Signal for Drinking, Craving, and Self-Efficacy - Pagni Broc; Ross Stephen; Kim Yuna; Bogenschutz Michael (Biological Psychiatry, 2026)

Cytochrome P450 Inhibition by Psilocybin and Psilocin: A Combined Molecular Dynamics and Enzymatic Screening Study - Andreia Machado Brito-da-Costa; Mariana Carvalho; Ricardo Jorge Dinis-Oliveira; Áurea Madureira-Carvalho; Sérgio F. Sousa; Diana Dias da Silva (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2026)

Role of Psychological support in sustaining Antidepressants effects in Psilocybin - Assisted Clinical - Gupta Gyandev; Yadav Ravina (JOURNAL OF ADVANCE AND FUTURE RESEARCH, 2026)

The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression. - Greenway KT; Garel N; Dinh-Williams LL; Thibault Lévesque J; Kaelen M; Dagenais-Beaulé V; de la Salle S; Erritzoe D; Looper K; Turecki G; Rej S; Richard-Devantoy S (The British journal of psychiatry: the journal of mental science, 2026)

High dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in Sprague-Dawley rats. - Bruno V; López-Canul M; Richardson B; Camarini R; Marcourakis T; Gobbi G (Journal of psychopharmacology (Oxford, England), 2026)

Landscape analysis of pre-registered clinical trials involving classical psychedelics. - Uyar A; Forbrich L; Lueken U; Evens R (Journal of psychopharmacology (Oxford, England), 2026)

Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review. - Viljoen G; Walter H; Bendau A; Koslowski M; Betzler F (Journal of psychopharmacology (Oxford, England), 2026)

The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research. - Stocker K; Hartmann M; Schmid Y; Vogt SB; Becker AM; Ley L; Straumann I; Arikci D; Klaiber A; Erne L; Vizeli P; Holze F; et al. (Journal of psychopharmacology (Oxford, England), 2026)

The helioscope effect: A new framework for evaluating trauma-related memory processing in psychedelic experiences. - Diehl VJ; Calder AE; Hasler G (Journal of psychopharmacology (Oxford, England), 2026)

The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures. - Scholle P; Wenke Š; Nekovářová T; Zaytseva Y; Tylš F; Brunovský M; Horáček J; Andrashko V; Koudelka V; Viktorinová M; Viktorin V; Hájková K; et al. (Journal of psychopharmacology (Oxford, England), 2026)

Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms. - Garcia Garcia M; Belahda D; Graux C; Serrand C; Igounenc N; Sergent F; Mura T; Luquiens A (Journal of affective disorders, 2026)

Insights into psilocybin use among people with bipolar disorder: A thematic analysis of Reddit posts - Mills Laura; Rossell Susan L.; Carruthers Sean P. (Journal of Affective Disorders, 2026)

Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms - Domi Ana; Lucente Erika; Cadeddu Davide; Bengtsson Niklas; Smedler Erik; Adermark Louise (Neuropharmacology, 2026)

Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience. - Kerr-Gaffney J; Myrtle S; Askari F; Bird C; Modlin NL; Young AH; Rucker J (Journal of psychopharmacology (Oxford, England), 2026)

Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds. - Lewis BR; Reid MJ; Novick AM; Byrne K; Niciu MJ; Fonzo GA; Meyer TD; Feifel D; El-Mallakh RS; Soares J; Suppes T; Barrett FS (Journal of psychopharmacology (Oxford, England), 2026)

Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones. - Goldy SP; Sepeda ND; Hilbert SN; Bari BA; Garcia-Romeu A; Gukasyan N; Barrett FS; Yaden DB; Nayak SM (Psychiatry research, 2026)

Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamine - Courtes Alan C.; Myers Blake; Daly Noah; Jones Greg; Soares Jair C.; Zarate Carlos A.; Machado-Vieira Rodrigo (General Hospital Psychiatry, 2026)

Trends in first-time psychedelic and other hallucinogen use in the United States: Results from the National Survey on Drug Use and Health. - Montoy JCC; Wang RC; Coker AR; Anderson BT (Drug and alcohol dependence, 2026)

A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder - Moreno Francisco A.; Allen Katja E.; Wiegand Christopher B.; Dunne Rajan; Prickett James I.; Bayze Brian; Allen John J. B. (Journal of Psychopharmacology, 2026)

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression - Mertens Lea J.; Koslowski Michael; Betzler Felix; Brand Manuela; Evens Ricarda; Kärtner Laura; Jungaberle Andrea; Jungaberle Henrik; Majić Tomislav; Schmitz Christian N.; Ströhle Andreas; Scharf Dennis; et al. (JAMA Psychiatry, 2026)

Enlightenment in a Pill-Testing the Efficacy of Psilocybin - Hudson James I.; Pope Harrison G. (JAMA Psychiatry, 2026)

Psychological support in psychedelic-assisted therapy clinical trials: A systematic review. - Brusky B; M'Bailara K; Alla F; Barrault M (Journal of psychopharmacology (Oxford, England), 2026)

Trip killers: Addressing a critical knowledge gap in psychedelic research. - O'Mahony B; Harrington C; Harkin A; Lally N (Journal of psychopharmacology (Oxford, England), 2026)

Pharmacotherapy in Disorders of Consciousness: A Mechanism-Based Review. - Gillet A; Geron C; Vitello MM; Lejeune N (CNS drugs, 2026)

Effects of psychedelic use on authoritarian attitudes revisited. - Simonsson O; Lyons T; Marks J; Kettner H; Roseman L; Haijen E; Kaelen M; Carhart-Harris R (Journal of psychopharmacology (Oxford, England), 2026)

Associations between psychedelic use and migraine history in Swedish twins. - Simonsson O; Sun S; Wesseldijk LW; Ullén F; Osika W; Mosing MA (Journal of psychopharmacology (Oxford, England), 2026)

New Approach Methodologies and Open Access Tools Help Characterize Risks for DART, DNT, or Endocrine Effects From Exposure to Hallucinogens With Potential Pesticide Contaminants. - Silva MH (Birth defects research, 2026)

Pharmacotherapeutic Management of Depression in Patients With Cancer: A Review of Mechanistic and Clinical Evidence. - Hajivalizadeh S; Farahmand K; Kazemzadeh K; Hajivalizadeh G; Shamabadi A (Cancer reports (Hoboken, N.J.), 2026)

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM - Beidas Zeina; Ragnhildstveit Anya; Blackman Adam; Anderson Thomas; Fewster Emily; Syed Omer A.; Sobolenko Valentyne; Kanca Ismail Kaan; Son Tatiana; Farb Norman; Petranker Rotem (BJPsych Open, 2026)

Therapeutic Potential of Psilocybin in Alcohol and Opioid Use Disorders: A Promising Role for Psychedelics - Zolali Elmira; McMahon Lance R.; Obeng Samuel (Pharmaceutical Sciences, 2026)

Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations - Nayak SM; Sepeda ND; Dick MN; Tiwari P; Zahid Z; Sayalı C; Weiss BM; Yaden DB; Garcia-Romeu A; Barnett BS; Barrett FS. (medRxiv, 2026)

Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled Settings - Kurt Stocker; Matthias Hartmann; Frederick S. Barrett; William A. Richards; Nathan D. Sepeda; Laura Ley; Anna M. Becker; Friederike Holze; Matthias E. Liechti (Repository for Publications and Research Data (ETH Zurich), 2026)

Characterizing psilocybin’s effects on nociception and thermoregulation in preclinical pain models - Tyler Girard; Boris Heifets; Robert Sapolsky; X Chen; Stanford University (Stanford Digital Repository, 2026)

Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption - Briggs Dylan; Sease Thomas B.; Menou Ruthie; Perkins David R. (Behavioral Sciences, 2026)

Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study) - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2026)

A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back Pain - Joshua Woolley; MD; PhD (ClinicalTrials.gov, 2026)

The Ecstasy of Gold in Neurodiversity: Focus on the Use of Psychedelics in Autism Spectrum Disorder - Marini S; De Berardis D. (Preprints.org, 2026)

Evaluating the evidence for repressed memory recovery in psychedelic contexts - Anne-Fiona Griesfeller; Lotte Kooman; Lilian Kloft-Heller; Samuli Kangaslampi; Johannes G Ramaekers; Henry Otgaar (Psychopharmacology, 2026)

A128-Channel Wireless Wearable Myolink (W2 Myolink): Functional Characteristics and Multidisciplinary Experiments - Zajaczkowski M; Koutsoftidis S; Sheeraz M; Barsakcioglu DY; Jia T; McGeady CA; Kundu A; Pizzi M; Tatti F; Bashford J; Bhavesh P; Farina D; et al. (Research Square, 2026)

Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review. - Magnani L; Ghirotto L; Fesce F; Re T; Tanzi S; Amerio A; Costanza A (BMJ supportive & palliative care, 2026)

Specific and Multi-Product Clade I and Clade IV Sesquiterpene Synthases Contribute to the Psilocybe cubensis Volatilome. - Schober S; Dorfmann L; Walther K; Blei F; Chadeayne AR; Gressler M; Bartram S; O'Connor SE; Hoffmeister D (Chembiochem: a European journal of chemical biology, 2026)

The Harmonious Dance: A Narrative Review on Psychedelics and Music in Therapeutic Settings. - Wang H; Li X; Yu F; Wang X (Current neuropharmacology, 2026)

Fusing Specialized Surveys of Rare Populations to Larger Surveys for Generalized Inference: Cross-Sectional Survey Study. - Rockhill KM; Bemis EA; Schow N; Olsen HA; Beekman K; Fox EJ; Monte AA; Black JC (Journal of medical Internet research, 2026)

157. Opposing 5-HT Receptors Modulate Psilocybin's Action on Dendritic Calcium Dynamics - Neil K. Savalia; Lingxiao Shao; Cory Knox; A. Gilbert; Quan Jiang; Alex Kwan (Biological Psychiatry, 2026)

Exploring Psilocybin-Assisted Schema Therapy: A Conceptual Framework for Potential Therapeutic Synergies in Personality Disorders. - Barbieri A (Trends in psychiatry and psychotherapy, 2026)

“Large-Scale and Local Functional Connectivity Changes Following Psilocybin Administration in Methamphetamine Use Disorder - Chaganti Joga; Siefried Krista J; Vyakaranam Veda S; Acheson Liam; Brett Jonathan (American Journal of Neuroradiology, 2026)

Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia - Askey Tatum; Allen-Ross Daniel; Luzyanin Daniil; Lasrado Reena; Gilmour Gary; Hunt Stephen P.; Tamagnini Francesco; Ahmed Maqsood; Stephens Gary J.; Maiarú Maria (Communications Biology, 2026)

Psilocybin use among Basotho healers and non-healers in southern Africa - Stark-Elster Eli; Sethathi Mamosebetsi; van der Merwe Breyten; Nayak Sandeep Manel; Yaden David Bryce; Singh Manvir (OSF Preprints, 2026)

Methamphetamine-Fentanyl Polysubstance Administration Produces Social Deficits and Corticolimbic Stress-Reward Circuit Adaptations. - Salinsky LM; Fox JL; Diaz KC; Timmons BC; Ferguson SM (Research square, 2026)

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder - Portland VA Research Foundation; Inc (ClinicalTrials.gov, 2026)

A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD) - Usona Institute (ClinicalTrials.gov, 2026)

Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy - Kyle Greenway (ClinicalTrials.gov, 2026)

Distinct Modulatory Effects on Affective Biases by Different Serotonergic Psychedelics and MDMA in Male Rats: Possible Implications for Antidepressant Effects - Hinchcliffe JK; Bartlett J; Thomas CW; Golden CT; Gilmour G; Bortolotto ZA; Robinson ES. (bioRxiv, 2026)

Psilocybin as an alternative to conventional treatments: A systematic review - Cahuasqui-Mendoza Deivid Antonio (Gaceta Médica de Caracas, 2026)

Prevalence and Correlates of Past-Year Psilocybin Use in the United States - Yang Kevin H.; Eun Avery; Palamar Joseph J. (American Journal of Psychiatry, 2026)

Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site. - Baral A; Pan Y; Hlaing WM; Garcia-Romeu A; Pinheiro PS; Vidot DC (Cancer causes & control: CCC, 2026)

Structural plasticity and enhanced fear extinction following psilocybin in chronically stressed mice. - Knox CA; Woodburn SC; Gilbert AD; Schlotzhauer JM; Kwan AC (bioRxiv: the preprint server for biology, 2026)

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission - University of Colorado; Denver (ClinicalTrials.gov, 2026)

The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes - Khosravi Mohsen; De Berardis Domenico; Tusconi Massimo (Mental Wellness, 2026)

Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled Trials - Siti Nashria Rusdhy; Andrian Fajar Kusumadewi; Carla Raymondalexas Marchira; Mustika Suci Mahardikaningrum; Teresa Lalita Wiryarini; Devira Ayu Wulandari (Open Access Indonesian Journal of Medical Reviews, 2026)

Serotonergic Polypharmacology of 2-Halogenated Tryptamines. - Yacoub J; Bray E; Bayyat J; Glatfelter GC; Leake A; Buitrago EM; Maitland AD; Partilla J; Cavalco NG; Schalk SS; Lammers JC; Baumann MH; et al. (bioRxiv: the preprint server for biology, 2026)

Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twins - Drange Sivert; Cohen Jacob; Johansen Sys Stybe; Dunkley Ben; Palner Mikael (Frontiers in Psychiatry, 2026)

Sustained Effects of Low-to-Moderate Doses of Psilocybin on Brain Connectivity - Bhagavan C; Dandash O; Carter O; Bryson A; Kanaan RA. (medRxiv, 2026)

Comparative Medico-Legal Frameworks for Psilocybin Regulation: A March 2026 Update - Brinzei OV. (Preprints.org, 2026)

Psychedelics: Historical Context, Emerging Science, and Future Clinical Frontiers - Vipul Janardan; Amit Khanna; Om Prakash; Anadrika Debbarma; SK Mathur (Journal of Mental Health Disorders, 2026)

Psychedelics and Autism Therapy: A Review of Current Research and Future Directions. - Gondi CS; Gnanamony M; Gondi TP; Nersesyan L; Demirkhanyan L (Current issues in molecular biology, 2026)

Impact of psilocybin and Psilocybe cubensis extract on gut microbiota in Wistar Han rats - Francisco Sacadura; Cláudia Marques; Andreia Machado Brito-da-Costa; Mariana Carvalho; Helena Carmo; Ricardo Jorge Dinis-Oliveira; Áurea Madureira-Carvalho; Diana Dias da Silva (Science Letters, 2026)

Psilocybin and Psilocybe cubensis extract exhibit divergent behavioural and toxicological effects in rats - Diana Dias da Silva; Andreia Machado Brito-da-Costa; Francisco Sacadura; Mariana Carvalho; Helena Carmo; Ricardo Jorge Dinis-Oliveira; Áurea Madureira-Carvalho (Science Letters, 2026)

Investigating Psychedelic Tryptamines: Extraction and Quantification from Psilocybe Mushrooms - Beatriz P. Senra; Ricardo Jorge Dinis-Oliveira; Carlos J. A. Ribeiro (Science Letters, 2026)

Neural Entropy and Cognitive Flexibility: A Research Agenda for Psilocybin-Assisted Therapy [FUTURE DIRECTIONS v1.0] - Juan Moisés de la Serna de la Serna (Zenodo (CERN European Organization for Nuclear Research), 2026)

Psilocybin reshapes cortical inhibition through selective interneuron recruitment. - Davoudian PA; Jiang Q; Knox CA; Savalia NK; Shao LX; Wilson J; Weiner AM; Chong CW; Liao C; Nothnagel JD; Sakurai T; Kwan AC (bioRxiv: the preprint server for biology, 2026)

Substance use predictors of arrest and self-reported criminal behavior in the United States: The role of psychedelics and rarely used drugs. - Norris JJ (Journal of psychopharmacology (Oxford, England), 2026)

Psilocybin’s Kinematic Effect on Manual Dexterity - Klintefors P; Bhagavan C; Kanaan R; Bryson A; Berlowitz D; Attard Z; Carter O. (Research Square, 2026)

Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration - Jóźwiak-Bębenista M; Stasiak A; Sienkiewicz M; Kwiatkowski P; Kowalczyk E. (Preprints.org, 2026)

Psilocybin use in Puerto Rico: Patterns, motivations, and personality correlates from an online survey - Vélez Rodríguez Jean C.; Duquesne-Maldonado Yanice; Hernández Torres Julián M.; Da'Luz Sant'Ana Istoni; Nazario Cruz M. (Journal of Psychedelic Studies, 2026)

Psilocybin Trends in States That Decriminalized Use - Black Joshua C.; Bau Gabrielle E.; Cook Ryan R.; Bemis Elizabeth A.; Monte Andrew A. (JAMA, 2026)

Effects of a single dose of psilocybin on diet-induced weight loss in obese mice - Keenan Ryan J.; Haque Rifa T.; Jin Xiangjun; Mustafa Tomris; Homman-Ludiye Jihane; Elysee Kayla; Wee Zi Shan; Simonds Stephanie E.; Foldi Claire J.; Cowley Michael A. (Translational Psychiatry, 2026)

A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience - Back Anthony L.; McGregor Bonnie A.; Thorn Leslie L.; Harvey Kalin; Blom Dianna; Callan George; Guy John; Kumar Sameet; Hershberg Rob; Layer Melissa; Levin Jackie; Myers Susanna; et al. (Frontiers in Public Health, 2026)

CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial - Section for Affective Disorders; Northern Stockholm Psychiatry (ClinicalTrials.gov, 2026)

Psilocybin acutely reduces low-frequency BOLD power and frequency-specific connectivity - Olsen AS; Larsen K; McCulloch DE; Ganz M; Madsen MK; Ozenne B; Knudsen GM; Rehman Nu; Fisher PM. (bioRxiv, 2026)

Psilocybin for Treatment of Prolonged Grief Disorder: An Open-Label Feasibility Study Protocol - Penberthy J. Kim; A. Wise Fatma; Cherup Nicholas; Penberthy J. Morgan; Mitchell Evaline; Burns Madeline; Akinlade Oluwafunmilayo; Chung David; Parmar Harshit; Singer Jonathan (Psychoactives, 2026)

Observing the mind under psychedelics: conceptual metaphors used following four once-weekly macrodoses of psilocybin - Rundquist Eric; Monasterio López Diego Nicolás; Oyarzo Alvarado Juan Jonathan; Carhart-Harris Robin; Pasquini Lorenzo; Vinson Erin; Girn Manesh; Ostrand Avery; Allison Kate; Kettner Hannes; Miller Catriona; Griffith Sydney; et al. (Philosophical Psychology, 2026)

Psilocybin elicits a conserved glucocorticoid-responsive gene signature across five 5-HT2A receptor-rich brain regions in rat. - Veysi A; Atanasovski D; Ardalan M; Motamed N; Eriksson E (Acta neuropsychiatrica, 2026)

Sex-specific increased reactivity of the PVT and prolonged PVT→CeA circuit engagement following psilocin administration - Effinger D. P.; Hoffman J. L.; Quadir S. G.; Rollison C. S.; Toedt D.; Echeveste Sanchez M.; High M. W.; Hodge C. W.; Herman M. A. (Nature Communications, 2026)

Additional file 1 of Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression - Nikita Sanati Morel; Dea Siggaard Stenbaek; Johan Lundberg; Maria Beckman (Figshare, 2026)

Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression - Morel Nikita Sanati; Stenbaek Dea Siggaard; Lundberg Johan; Beckman Maria (BMC Medical Education, 2026)

Brain-MGF: Multimodal Graph Fusion Network for EEG-FMRI Brain Connectivity Analysis Under Psilocybin - Yap Sin-Yee; Noman Fuad; Loo Junn Yong; Stoliker Devon; Khajehnejad Moein; Phan Raphaël C.-W.; Dowe David L.; Razi Adeel; Ting Chee-Ming (2026 IEEE 23rd International Symposium on Biomedical Imaging (ISBI), 2026)

Severe Illness Associated with Eating Mushroom-Containing Chocolate Products - United States, January-October 2024. - Rumph JT; Winquist A; Troeschel AN; Pulver S; Schnall AH; Ebersole J; Yeh M; Burt B; Federman SL; Klontz K; Dasenbrock C; Leahy HL; et al. (MMWR. Morbidity and mortality weekly report, 2026)

Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder - University of California; Los Angeles (ClinicalTrials.gov, 2026)

Altered States of Consciousness and the Subconscious Mind: A Comprehensive Comparative Review of Disciplines, Neurobiological Mechanisms, Clinical Applications, and Philosophical Frameworks - Including Life Between Lives and Transpersonal Hypnotherapy - Gallardo LM. (Preprints.org, 2026)

A living systematic review, meta-analysis and open-data resource of randomized controlled trials of psilocybin treatment for symptoms of depression - Singleton S. Parker; Sevchik Brooke L.; Lahey Analiese; Cuijpers Pim; Harrer Mathias; Jones Megan T.; Nayak Sandeep M.; Strain Eric C.; Vandekar Simon N.; Dworkin Robert H.; Scott J. Cobb; Satterthwaite Theodore D. (Nature Mental Health, 2026)

Hallucinogenic Therapy in Alzheimer's Disease targeting Mitochondria-Associated Membranes. - Minauro-Sanmiguel F; Vargas-Perez H (Neuroscience, 2026)

Complete biosynthesis of psychedelic tryptamines from three kingdoms in plants. - Berman P; Höfer J; Mehlman H; Almekias-Siegl E; Khersonsky O; Dong Y; Heinig U; Sulimani L; Hao LK; Cohen S; Peleg Y; Meir S; et al. (Science advances, 2026)

Psilocybin and human longevity - Lerer Leonard (npj Aging, 2026)

Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2026)

Effects of Psilocybin in Obsessive Compulsive Disorder - Johns Hopkins University (ClinicalTrials.gov, 2026)

"I've Done My Research": Psychedelics, PTSD, and the Therapeutic Alliance. - Stubbe DE (Focus (American Psychiatric Publishing), 2026)

26-CCC-15854-ACC TALK ABOUT A BAD TRIP!: PSILOCYBIN USE WITH PRE-EXISTING CARDIOVASCULAR DISEASE, A CASE REPORT - Buchanan Christine (JACC, 2026)

MedCheck: FDA Approves Novel Antipsychotic Milsaperidone; Designates Psilocybin Analogue as Breakthrough Therapy for Postpartum Depression, and More! - Richmond Linda M. (Psychiatric News, 2026)

Psilocybin: Wirksam, aber kein Wundermittel - Pichler Helena (MMW - Fortschritte der Medizin, 2026)

Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications - Meshkat Shakila; Jha Manish K.; Bhat Venkat (Focus, 2026)

Psilocybin mitigates chronic behavioral and neurobiological alterations in a rat model of recurrent intimate partner violence-related brain injury. - Allen J; Sun M; Baker TL; Dames S; Kryskow P; Christie BR; McDonald SJ; Shultz SR (Molecular psychiatry, 2026)

The effect of dextromethorphan on reward-related behaviors: A systematic review of preclinical and clinical evidence. - Teopiz KM; Le GH; Wong S; McIntyre RS (Journal of affective disorders, 2026)

Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial. - Schindler EAD; Gottschalk CH; Pittman BP; D'Souza DC (Headache, 2026)

Psilocybin Production With Genetically Modified Aspergillus nidulans Under Pressurized Conditions. - Weiser S; Jung S; Bardl B; Kufs JE; Janevska S; Valiante V; Hoffmeister D; Regestein L (Biotechnology and bioengineering, 2026)

Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols - Swieczkowski Damian; Kwaśny Aleksander; Sadko Krzysztof; Cubała Wiesław Jerzy (European Neuropsychopharmacology, 2026)

Effects of psilocybin and chronic mild stress on microglial activation in rat spinal cord: an ex vivo analysis. - Olejnik P; Kamińska K; Gołembiowska K; Kasarełło K (Pharmacological reports: PR, 2026)

Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin - Žuljević Marija Franka; Mijatović Antonija; Orhanović Renata; Goasdoué Glenn; Gujinović Diana (Journal of Clinical Epidemiology, 2026)

Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis - Syed Omer A.; Tsang Benjamin; Nestor Sean M.; Lipsman Nir; Husain Muhammad Ishrat; Alam Fahad; Giacobbe Peter (Neuroscience & Biobehavioral Reviews, 2026)

PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial. - Downar J; Lapenskie J; Anderson K; Parsons G; Polskaia N; Lalumiere G; Lawlor P (Palliative medicine, 2026)

Regulatory ambiguity and governance challenges for psilocybin mushrooms in Brazil - Nogueira Marcel; García-Hernández Solimary; Roberto Gleicy Sotéro; Rodrigues Daniel Cardoso (International Journal of Drug Policy, 2026)

Serotonergic modulation of cortical gamma synchronization: right-lateralized psilocin effects on 40 Hz auditory steady-state responses in rats - Griškova-Bulanova Inga; Vejmola Čestmír; Páleníček Tomáš (Journal of Neurophysiology, 2026)

Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use. - Bhatt KV; Friedman J; Benster L; Narasimhan R; Yang K; Mishra J; Weissman CR; Ramanathan D (Community mental health journal, 2026)

Psychedelic-Assisted Therapy: Breakthrough for Whom? - Adams DR; Xu KY; Cabassa LJ (Psychiatric services (Washington, D.C.), 2026)

Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action. - Kazdan J; Ladha KS; Husain MI (Pharmacology research & perspectives, 2026)

An international mega-analysis of psychedelic drug effects on brain circuit function. - Girn M; Doss MK; Roseman L; Preller KH; Palhano-Fontes F; Pasquini L; Barrett FS; Mallaroni P; Mason NL; Timmermann C; McCulloch DE; Fisher PM; et al. (Nature medicine, 2026)

Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations. - Marazziti D; Gambini M; Gurrieri R; Russomanno G; Sità G; Pescini E; Digiuseppe FR; Mucci F (Expert opinion on pharmacotherapy, 2026)

The astrocytes in the prefrontal cortex contribute to the rapid antidepressant-like effects of psilocybin in the chronic restraint stress mouse model - Qiao Yong-xing; Dai Wei; Yao Yi-shan; Wei Qian-qian; Yue Chen-xing; Yin Yong-yu; Li Yun-feng; Zhang Li-ming (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2026)

Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness-a psychometric analysis using the PES100 in controlled psychedelic studies - Kurt Stocker; Matthias Hartmann; Frederick S. Barrett; Willam Richards; Nathan D. Sepeda; Isabelle Straumann; Aaron Klaiber; Severin B. Vogt; Livio Erne; Laura Ley; A. Becker; Patrick Vizeli; et al. (Religion Brain & Behavior, 2026)

Classic psychedelics in obsessive-compulsive disorder: a circuit-based framework - Saif S. Ali; Robin L. Carhart-Harris; Karl G. Sieg (Nature Mental Health, 2026)

Reshaping human neurons. - Maltman JL; González-Maeso J (eLife, 2026)

Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric Disorders - Kenji Hashimoto; Feyza Arıcıoğlu; Mesut Çetin (Psychiatry and Clinical Psychopharmacology, 2026)

Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression - Sunnybrook Health Sciences Centre (ClinicalTrials.gov, 2026)

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder - Indiana University (ClinicalTrials.gov, 2026)

Strong alliance, weak conclusions: Comment on Goodwin et al. (2026) “The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression” - Max Wolff; Samuli Kangaslampi; Richard J. Zeifman; Moritz Spangemacher (PsyArXiv, 2026)

Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin - Smith Katharine A.; Harcourt Edward; Cipriani Andrea (The British Journal of Psychiatry, 2026)

Unlocking 'stuckness' and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic-assisted therapy for substance use and mental health problems. - Catchlove SJ; Oliver K; Savic M; Arunogiri S (Addiction (Abingdon, England), 2026)

Associations Between Psilocybin Use Motives and Cognitive, Affective, and Behavioural Self-Stigma - Knibb Graeme; Ward Ruby; Christiansen Paul; Roberts Carl Alexander (Substance Use & Misuse, 2026)

Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression - Federal University of Latin American Integration (ClinicalTrials.gov, 2026)

Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons - Schmidt Malin; Hoffrichter Anne; Davoudi Mahnaz; Horschitz Sandra; Lau Thorsten; Meinhardt Marcus W; Spanagel Rainer; Ladewig Julia; Köhr Georg; Koch Philipp (eLife, 2026)

Psilocybin Attenuates Cortical Representations of Aversion in the Mouse Auditory Cortex. - Johnson JD; Tian R; Etemadi Y; Li Z (bioRxiv: the preprint server for biology, 2026)

Classic psychedelic medicines for adolescent refractory mental health disease - Aly Shah Aziz (Journal of Psychedelic Studies, 2026)

Psychedelic Experiences and Finitude in Serious Illness: A Qualitative Synthesis - Ana Cláudia Mesquita Garcia; Geovanna Maria Isidoro; Cremilson de Paula Silva (Journal of Pain and Symptom Management, 2026)

Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial - Broc A Pagni; Stephen Ross; Sarah Mennenga; Snehal R Bhatt; Richard J. Zeifman; Petros Petridis; Brennan Carrithers; Lindsay Worth; Samantha Podrebarac; Lindsey Owens (PsyArXiv, 2026)

Psilocybin shapes the slow, global propagation of brain activity over the cortical layout of 5HT2a receptors - Mäki-Marttunen Verónica (Communications Biology, 2026)

Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD) - Skalski Piotr; Pękacka-Falkowska Katarzyna; Pluto-Prądzyńska Agnieszka; Owecki Michał K. (Brain Sciences, 2026)

Psychedelic-Induced Constraint Destabilization and Reconstruction as a Mechanism for Cognitive Reset - Stanley Everett Sambey (Zenodo (CERN European Organization for Nuclear Research), 2026)

Psilocybin Prolongs the Neurovascular Coupling Response in Mouse Visual Cortex. - Zirkel RT; Isaacson M; Liao C; Yi M; Yamaguchi K; Rivera D; Kuceyeski A; Nishimura N; Kwan AC; Schaffer CB (bioRxiv: the preprint server for biology, 2026)

The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial. - Anders Fink-Jensen; MD; DMSci (ClinicalTrials.gov, 2026)

Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial - Medical University of Vienna (ClinicalTrials.gov, 2026)

Integrated 5-HT -TrkB and G protein signaling in serotonergic psychedelic responses. - Taddei-Tardón M; Medina-Rodríguez L; Maltman JL; Hudson S; Potukanuma S; Jiménez JH; Martín-Guerrero SM; González-Maeso J; López-Giménez JF (bioRxiv: the preprint server for biology, 2026)

“You can only take your clients as far as you’ve been yourself”: examining the intersections between psychedelic-assisted therapy, lived-living experience, and clinical practice - Jordan J. Negrine; Stephen Bright; Monica J. Barratt; Matthew Pennell; Anthony Barnett; James Bennett-Levy; Timothy Piatkowski (Drugs Education Prevention and Policy, 2026)

Psychedelic-Assisted Psychotherapy: Attitudes of Law Enforcement and Military Personnel - Alexandra Hopkins; Cassandra A. Bailey; Emily Rybak; Mia M. Ricardo (Journal of Police and Criminal Psychology, 2026)

Psilocybin, Lp(a), CAC, Niere und Darmkrebs - Evidenz-Quickies KW12 - Nößler Denis (EvidenzUpdate, 2026)

When I use a word... The psychedelic mind’s eye - J K Aronson (BMJ, 2026)

Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies - University of New Mexico (ClinicalTrials.gov, 2026)

Psychedelics in functional disorders: A scoping review. - Bhagavan C; Carter O; Bryson A; Dandash O; Kanaan R (Progress in neuro-psychopharmacology & biological psychiatry, 2026)

Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil. - Portes MAM; Bertoglio LJ (Journal of psychoactive drugs, 2026)

Beyond the Genomic Storm: Evaluating Tabernanthalog as a Potential Scaffold for Silent Neuroplasticity and Broad-Spectrum Therapy. - Anchesi I; Raffaele I; Astorino MF; Lui M; Calabrò M; Cipriano GL (International journal of molecular sciences, 2026)

PSILOCYBIN AS AN ADJUNCTIVE TREATMENT FOR DEPRESSION AND PSYCHOLOGICAL DISTRESS IN ONCOLOGY: CURRENT EVIDENCE AND CLINICAL IMPLICATIONS - Komarczewska Anna; Kociński Michał; Iglewski Patryk; Pietrasz Michał; Idziński Jakub; Lubomska Anna (International Journal of Innovative Technologies in Social Science, 2026)

Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies - Farré-Colomés Àlvar; Rublinetska Olga; Soto-Angona Óscar (Discover Mental Health, 2026)

Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distribution - Matsukubo Jenna; Friesen Erik Loewen; MacDonald-Spracklin Rachael; Iseman Rachael; Solmi Marco; Fiedorowicz Jess G.; Fischer Benedikt; Myran Daniel T. (Canadian Journal of Public Health, 2026)

Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder - Johns Hopkins University (ClinicalTrials.gov, 2026)

Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study - Gustavo Vazquez (ClinicalTrials.gov, 2026)

Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs - Williamson Samuel E.; Burkhartzmeyer Elise K.; Faley Michael T.; Ohana Rachel F.; Guzei Ilia A.; Valley Mike; Cali James J.; Sherwood Alexander M. (ACS Chemical Neuroscience, 2026)

A fungus among us: investigating queensland’s largest magic mushroom growing operation - Kate Brough; Corinna Lange (Australian Journal of Forensic Sciences, 2026)

Hallucinogens for Mood and Anxiety Disorders: A Critical Review of Psychedelic-Assisted Therapies - Georgia Chlebek (ThinkIR: The University of Louisville's Institutional Repository (University of Louisville), 2026)

Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease - Johns Hopkins University (ClinicalTrials.gov, 2026)

Explainable AI framework for psilocybin depression treatment optimization - Sungheetha Akey; Rajesh Sharma R.; Aroba Oluwasegun Julius; Mahapatra Sheila; Mahendhiran P. D. (Frontiers in Computer Science, 2026)

Psychedelic Terminology Preference in the 2024 National Survey Investigating Hallucinogenic Trends (NSIHT). - Lyons FE; Rockhill KM; Fox EJ; Bemis EA; Black JC; Monte AA; Dart RC (Journal of psychoactive drugs, 2026)

Editorial: Psychedelic substances and neurological diseases: from basics to clinical application - Alessandra Linardi; Ariadiny Lima Caetano; Rodrigo Portes Ureshino (Frontiers in Pharmacology, 2026)

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder - Johns Hopkins University (ClinicalTrials.gov, 2026)

The renaissance of research on psychedelics in child and adolescent psychopharmacology. - Crocq MA; Auby P (Child and adolescent psychiatry and mental health, 2026)

Differential Effects of Acute and Chronic Fluoxetine on Psychedelic-Induced Behavior in Mice: Implications for Clinical Trials. - Wood BJ; Vest MF; Carfagno C; Bartley KR; Sharma P; Halberstadt AL; Blough BE; Murnane KS (ACS pharmacology & translational science, 2026)

Digital Intervention for Psychedelic Preparation (DIPP): protocol for a randomised controlled feasibility trial comparing meditation- and music-based programmes in healthy volunteers. - McAlpine R; Jaglinska M; Jedlovszky K; Kuc J; Castro A; Piot A; Timmermann C; Skipper JI; Sacchet MD; Kamboj SK (BMJ open, 2026)

Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional Health - University of Alabama at Birmingham (ClinicalTrials.gov, 2026)

Psilocybin-facilitated Treatment for Chronic Pain - University of Alabama at Birmingham (ClinicalTrials.gov, 2026)

Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study - Yale University (ClinicalTrials.gov, 2026)

Oregon's Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training Programs - Jason Luoma; Kim Hoffman; Adie Wilson-Poe; Ximena Levander; Alissa Bazinet; Ryan Cook; Dennis McCarty; Kellie Pertl; Sarann Bielavitz; Devin Gregoire (PsyArXiv, 2026)

Discovery of the closest free-living relative of the domesticated 'magic mushroom' Psilocybe cubensis in Africa. - Bradshaw AJ; Sharp C; Van Der Merwe B; Tremble KS; Dentinger BTM (Proceedings. Biological sciences, 2026)

Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders. - Chauhan SB; Akhtar N; Jain C; Singh I (CNS & neurological disorders drug targets, 2026)

Age moderates the relationship between psychedelics use and mental health in naturalistic settings - Gregorio GD; Basset S; Manmohan H; Nixon WC; Pogaku A; Zhou J; Sanderson DJ; Lengieza ML; Bocchio M. (Research Square, 2026)

Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response - Floris G; Jefferson SJ; Rondeau J; Yu AL; Menniti FS; Kwan AC; De Aquino JP; Krystal JH; Pittenger C; Kaye AP. (bioRxiv, 2026)

Psilocybin or Nicotine Patch for Smoking Cessation - Johnson Matthew W.; Naudé Gideon P.; Hendricks Peter S.; Garcia-Romeu Albert (JAMA Network Open, 2026)

Behavioural investigations of psilocybin in non-human animals 1962-2021: A scoping review - Shore Ronald; Dobson Kat; Thomson Nina; Barnim Nigel; Bergman Hailey; Rideout Katie; McKeown Sandra; Olmstead Mary C.; Goldie Craig; Dumont Eric (Journal of Psychedelic Studies, 2026)

“Diversity makes the richness of humanity”: The emergence and persistence of mental imagery after self-reported psilocybin truffles intake in an autistic woman with “blind imagination” (aphantasia): A33-month retrospective case report - Rebecchi Kevin (Journal of Psychedelic Studies, 2026)

Substance-induced manic psychosis in which delusions were corroborated by a chatbot - case report - Shah S; Morrin H. (Research Square, 2026)